Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
Chemomab Therapeutics Ltd. is dedicated to the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company is headquartered in Tel Aviv, Israel.
52W High
$9.84
52W Low
$2.99
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.55
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
13.00
EV/EBITDA (<8 favorable)
0.33
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
1.65
Ownership
BalancedSource: Overview
Insiders (1–5% typical)
16.73%
Institutions (25–75% balanced)
25.92%
Shares Outstanding
5,191,100
Float
321,955,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-2.00
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-1.20%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentumValue
-0.2999
Previous
-0.3123
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025